All Posts Tagged: radiomics

Medexprim semi-finalist at the SIIM 2018 Innovation Challenge

The 8 semi-finalists have been announced for the SIIM (Society for Imaging Informatics in Medicine) 2018 Innovation Challenge. Medexprim is proud that his project was selected and recognized by the medical imaging informatics community as one of the most impacting innovation in the field. Our project is entitled : “Unleash the potential of biomedical images archives and associated data for research and big data projects”.

Come and visit us at #SIIM2018 to know more.

More on the SIIM Innovation Challenge.

Read More

Let’s meet at RSNA 2017!

Medexprim is proud to have been selected to be part of the first ever RSNA Start-Up Showcase.

Come and visit us – North Hall B @ booth 6455B.

Read More

Participation in the i2b2 2017 European meeting on Oct. 5 and 6

The famous open-source clinical data warehouse community (see https://www.i2b2.org/) will hold its european academic meeting on Oct. 5 and 6 in Paris. To this occasion, Karine Seymour will present how Radiomics Enabler® can integrate with i2b2 or any other clinical data warehouse. By doing so, we  extend clinical data warehousing with image extraction capabilities and enable population based  radiomics studies. More information on the conference and program on http://blogs.aphp.fr/i2b2.

Read More

White paper: Scientific and economic valorisation of biomedical images archives (PACS) in medical research

Authors: Andrea Vaglienti & Karine Seymour

Existing biomedical imaging data are a fuel for the development of image related applications. In this paper we study 4 fields: in-silico clinical trials, imaging biomarkers, radiomics and imaging cognitive tools, which all constitute a major scientific point of interest and have great market expectations. Be prepared to value your existing imaging data, both scientifically and economically!

There is a change of paradigm in the medical R&D process. Up to recently, randomized controlled trials were the gold standard, took years and data were discarded after the trial, especially if the trial failed. We now know that analysing all clinical trial data and using real-world evidence

Read More